Hearing Loss, Complete — Evaluation of a Bio-inspired Coding Strategy for Cochlear Implant Users
Citation(s)
Abbas PJ, Hughes ML, Brown CJ, Miller CA, South H Channel interaction in cochlear implant users evaluated using the electrically evoked compound action potential. Audiol Neurootol. 2004 Jul-Aug;9(4):203-13.
Botros A, Psarros C Neural response telemetry reconsidered: II. The influence of neural population on the ECAP recovery function and refractoriness. Ear Hear. 2010 Jun;31(3):380-91. doi: 10.1097/AUD.0b013e3181cb41aa.
Boulet J, White M, Bruce IC Temporal Considerations for Stimulating Spiral Ganglion Neurons with Cochlear Implants. J Assoc Res Otolaryngol. 2016 Feb;17(1):1-17. Review.
Cohen LT, Richardson LM, Saunders E, Cowan RS Spatial spread of neural excitation in cochlear implant recipients: comparison of improved ECAP method and psychophysical forward masking. Hear Res. 2003 May;179(1-2):72-87.
Cohen LT Practical model description of peripheral neural excitation in cochlear implant recipients: 5. refractory recovery and facilitation. Hear Res. 2009 Feb;248(1-2):1-14. doi: 10.1016/j.heares.2008.11.007. Epub 2008 Dec 7.
Galvin JJ 3rd, Fu QJ, Nogaki G Melodic contour identification by cochlear implant listeners. Ear Hear. 2007 Jun;28(3):302-19.
Heffer LF, Sly DJ, Fallon JB, White MW, Shepherd RK, O'Leary SJ Examining the auditory nerve fiber response to high rate cochlear implant stimulation: chronic sensorineural hearing loss and facilitation. J Neurophysiol. 2010 Dec;104(6):3124-35. doi: 10.1152/jn.00500.2010. Epub 2010 Oct 6.
Hughes ML, Castioni EE, Goehring JL, Baudhuin JL Temporal response properties of the auditory nerve: data from human cochlear-implant recipients. Hear Res. 2012 Mar;285(1-2):46-57. doi: 10.1016/j.heares.2012.01.010. Epub 2012 Feb 8.
Lai W, Dillier N Neural adaptation and the ECAP response threshold: a pilot study. Cochlear Implants Int. 2009;10 Suppl 1:63-7. doi: 10.1179/cim.2009.10.Supplement-1.63.
Miller CA, Abbas PJ, Brown CJ An improved method of reducing stimulus artifact in the electrically evoked whole-nerve potential. Ear Hear. 2000 Aug;21(4):280-90.
Miller CA, Abbas PJ, Robinson BK Response properties of the refractory auditory nerve fiber. J Assoc Res Otolaryngol. 2001 Sep;2(3):216-32.
Miller CA, Hu N, Zhang F, Robinson BK, Abbas PJ Changes across time in the temporal responses of auditory nerve fibers stimulated by electric pulse trains. J Assoc Res Otolaryngol. 2008 Mar;9(1):122-37. doi: 10.1007/s10162-007-0108-5. Epub 2008 Jan 17.
Negm MH, Bruce IC The effects of HCN and KLT ion channels on adaptation and refractoriness in a stochastic auditory nerve model. IEEE Trans Biomed Eng. 2014 Nov;61(11):2749-59. doi: 10.1109/TBME.2014.2327055. Epub 2014 May 29.
Omran SA, Lai W, Dillier N Pitch ranking, Melody contour and instrument recognition tests using two semitone frequency maps for Nucleus Cochlear Implants. EURASIP Journal on Audio, Speech, and Music Processing, 2011; 1-16.
Undurraga JA, Carlyon RP, Macherey O, Wouters J, van Wieringen A Spread of excitation varies for different electrical pulse shapes and stimulation modes in cochlear implants. Hear Res. 2012 Aug;290(1-2):21-36. doi: 10.1016/j.heares.2012.05.003. Epub 2012 May 11.
Zeng FG, Rebscher S, Harrison W, Sun X, Feng H Cochlear implants: system design, integration, and evaluation. IEEE Rev Biomed Eng. 2008;1:115-42. doi: 10.1109/RBME.2008.2008250. Epub 2008 Nov 5. Review.
Zhang F, Miller CA, Robinson BK, Abbas PJ, Hu N Changes across time in spike rate and spike amplitude of auditory nerve fibers stimulated by electric pulse trains. J Assoc Res Otolaryngol. 2007 Sep;8(3):356-72. Epub 2007 Jun 12.
Evaluation of a Bio-inspired Coding Strategy for Cochlear Implant Users
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
